Having characterised the antibodies, we used a validated C-terminal anti-mGlu3 antibody for a semi-quantitative immunoblot study of membrane protein from superior temporal cortex from a series of over 150 patients with schizophrenia and comparison subjects, who were genotyped for a GRM3 risk single nucleotide polymorphism (SNP). Here, GRM3 is linked to schizophrenia.